<img height="1" width="1" src="https://www.facebook.com/tr?id=1475348972529988&amp;ev=PageView &amp;noscript=1">
Home
About
Why Milton Park?
Getting Here
Availability
News & Events
Work Here
Downloads
Contact Us

Adaptimmune announces £2.1m award

Published on: 30/03/2014

Adaptimmune, based at 91 Park Drive, announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

The funding award will be used to expedite Adaptimmune’s second clinical programme with a new TCR to enter the clinic in the UK. The award will support preclinical testing and regulatory approval for an initial pilot trial with a new TCR targeting an undisclosed protein found to be highly expressed in some forms of breast cancer and other cancer types. The trial is planned to start in 2015.

David Willetts, Minister for Universities and Science, said: “Britain has a world-leading life science cluster and Adaptimmune is a classic example of an innovative bioscience company that the Biomedical Catalyst Fund is designed to support. Its personalized therapy for cancer developed over 15 years in Oxford represents a potential breakthrough in cancer treatment for thousands of patients.”

Adaptimmune’s unique approach relies on the ability to fine-tune the affinity of the T cells to recognize the small protein fragments from intracellular cancer-specific proteins presented on the cell surface. 

James Noble, Adaptimmune’s Chief Executive Officer, said: “We are delighted to be announcing the Biomedical Catalyst Fund support for our next pipeline TCR and its path towards the clinic in 2015. We have a wide portfolio of cancer targets to be exploited in this way and our objective is to develop this pipeline of TCRs as rapidly as possible for the benefit of patients.”

Grants from the UK government-backed Biomedical Catalyst Fund totalling more than £120 million have been awarded to over 100 projects since the grant programme was introduced in 2012. The projects are led by UK-based small and medium-sized businesses and universities to accelerate the development of innovative solutions to healthcare challenges.

Adaptimmune represents one of the companies which have benefitted to date from the £180 million Biomedical Catalyst fund, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council. Details of all current clinical studies can be found on www.clinicaltrials.gov and more information about Adaptimmune can be found here >>>

  All news stories

Got some news to share?

Tell us about your achievements and what you have been up to.
Submit a story

Submit News

Submission Terms and Conditions

Terms and conditions for submitting an event, news story or directory item onto Milton Park’s website: www.miltonpark.co.uk

  1. miltonpark.co.uk is owned and run by MEPC Ltd, owners and managers of Milton Park, Oxfordshire
  2. All submissions are forwarded to the Marketing Executive for approval before upload
  3. Content submitted may be subject to change
  4. Content must be written in good English and grammatically correct
  5. If the submission is not deemed suitable or relevant it will not be uploaded
  6. Content must be clear, easy to read, understandable and relevant to the occupiers of Milton Park
  7. Once uploaded, items are subject to deletion at any time
  8. Upon submission, you will receive a confirmation email with a copy of these terms and conditions for reference
  9. Upon submission, items will be uploaded within 3 working days if suitable
  10. Classifieds are deleted after six months of upload
  11. News stories are archived monthly and remain on the Website for one year
  12. Events are archived monthly and remain on the Website for one year
  13. Companies listed on the website will be removed when leaving Milton Park